Alpha Or Leukocyte Patents (Class 424/85.7)
-
Publication number: 20110236348Abstract: The present invention includes therapeutic methods that include the administration of a compound of Formula I or II: or a pharmaceutically acceptable salt, solvate, and/or ester thereof, to a subject in need of such, and therapeutic methods that include the administration of such compounds with at least one additional active agent.Type: ApplicationFiled: June 3, 2011Publication date: September 29, 2011Applicant: Gilead Sciences, Inc.Inventors: Michael Graupe, Randall L. Halcomb
-
Publication number: 20110229438Abstract: The invention is directed to a method of treating infections by hepatitis C virus by administering N-{3-[(1R,2S,7R,8S)-3-(4-fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide and one or more additional antiviral compounds or pharmaceutical compositions containing such compounds.Type: ApplicationFiled: October 9, 2009Publication date: September 22, 2011Applicant: Anadys Pharmaceuticals, Inc.Inventors: Peter Dragovich, Peggy A. Thompson, Frank Ruebsam
-
Publication number: 20110229407Abstract: The present invention provides humanized, chimeric and human anti-alpha-fetoprotein antibodies, fusion proteins, and fragments thereof. The antibodies, fusion proteins, and fragments thereof, as well as combinations with other suitable antibodies, are useful for the treatment and diagnosis of hepatocellular carcinoma, hepatoblastoma, germ cell tumors carcinoma and other AFP-producing tumors.Type: ApplicationFiled: April 20, 2011Publication date: September 22, 2011Applicant: IMMUNOMEDICS, INC.Inventors: Hans J. Hansen, Zhengxing Qu, David M. Goldenberg
-
Publication number: 20110229411Abstract: The present invention concerns methods for assessing the sensibility of a subject to an anticancer treatment, for screening compounds which are useful for treating a cancer and for determining the likelihood of a metastatic relapse in a subject. The methods are based on the finding that a non-functional P2X7-elicited NALP3 inflammasome pathway in a subject is indicative of a resistance to treatment. The invention further concerns methods for treating a cancer and for restoring the sensitivity of the subject to a cancer treatment.Type: ApplicationFiled: November 27, 2008Publication date: September 22, 2011Applicants: INSTITUT GUSTAVE ROUSSY, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM), UNIVERSITE PARIS-SUD XIInventors: Lionel Apetoh, Antoine Tesniere, François Ghiringhelli, Laurence Zitvogel, Guido Kroemer
-
Publication number: 20110223230Abstract: A polymeric prodrug composition including a hydrogel, a biologically active moiety and a reversible prodrug linker. The prodrug linker covalently links the hydrogel and the biologically active moiety at a position and the hydrogel has a plurality of pores with openings on its surface. The diameter of the pores is larger than that of the biologically active moiety at least at all points of the pore between at least one of the openings and the position of the biologically active moiety.Type: ApplicationFiled: May 19, 2011Publication date: September 15, 2011Applicant: ASCENDIS PHARMA A/SInventors: Ulrich Hersel, Harald Rau, Robert Schnepf, Dirk Vetter, Thomas Wegge
-
Publication number: 20110223133Abstract: An inducing agent or enhancing agent, for the expression of HM1.24 antigen in hematopoietic tumor cells, comprising interferon ?, interferon ?, or the IRF-2 protein as an active ingredient, as well as an antitumor agent for hematopoietic tumors which comprises a combination of said inducing agent or enhancing agent and an antibody against HM1.24.Type: ApplicationFiled: April 13, 2011Publication date: September 15, 2011Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Masaaki KOSAKA, Shuji Ozaki, Yuji Wakahara
-
Publication number: 20110223233Abstract: A drug delivery device that includes a capsule for implantation into the body; the capsule further includes a reservoir for containing a substance such as a therapeutic agent, at least one port for allowing the substance to diffuse from or otherwise exit the reservoir, and a nanopore membrane in communication with the capsule at or near the exit port for controlling the rate of diffusion of the substance from the exit port. The device also includes an optional screen for providing structural stability to the nanopore membrane and for keeping the pores of the nanopore membrane clear. One embodiment of the drug delivery device includes an osmotic engine internal to the device for creating fluid flow through the device.Type: ApplicationFiled: April 29, 2011Publication date: September 15, 2011Applicant: Delpor, Inc.Inventors: FRANCIS J. MARTIN, ANTHONY A. BOIARSKI
-
Publication number: 20110223134Abstract: The present invention relates to novel Fused Tricyclic Silyl Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, B, C, D, M1, X1 and X2 are as defined herein. The present invention also relates to compositions comprising at least one Fused Tricyclic Silyl Compound, and methods of using the Fused Tricyclic Silyl Compounds for treating or preventing HCV infection in a patient.Type: ApplicationFiled: March 4, 2011Publication date: September 15, 2011Inventors: Anilkumar Gopinadhan Nair, Kerry M. Keertikar, Seong Heon Kim, Joseph A. Kozlowski, Stuart Rosenblum, Oleg B. Selyutin, Michael Wong, Wensheng Yu, Qingbei Zeng
-
Publication number: 20110217265Abstract: Screening methods are provided for identifying pharmacologic inhibitors of HCV amphipathic helix (AH) function, which inhibitors are useful in the prevention and treatment of HCV infection. Also provided are compounds useful in the inhibition of viral replication. The methods of the invention are based on the unexpected discovery that the presence of an AH, e.g. an AH of an HCV polypeptide, causes an increase in the apparent diameter of the vesicles. The methods of the invention provide for addition of AH peptides to lipid vesicles, for example in a high-throughput format; which addition may be performed in the absence or presence of a candidate pharmacologic agent. The change in apparent vesicle size is measured, and compared to control samples. An increase in vesicle size or aggregation is indicative of AH function being present; and a lack of increase is indicative that the AH function is absent or has been inhibited by a test agent.Type: ApplicationFiled: September 23, 2009Publication date: September 8, 2011Inventors: Jeffrey S. Glenn, Nam-Joon Cho, Wenjin Yang
-
Publication number: 20110217261Abstract: The present invention relates to pharmaceutical agents administered to a subject either in combination or in series for the treatment of a flaviviridae viral infection, for example, hepatitis C virus (HCV), wherein treatment comprises administering a compound effective to inhibit the function of the HCV NS5A protein and an additional compound or combinations of compounds having anti-HCV activity.Type: ApplicationFiled: August 5, 2010Publication date: September 8, 2011Inventors: Yat Sun Or, Christopher M. Owens, Bradley B. Brasher, Yao-Ling Qiu, Lijuan Jiang
-
Publication number: 20110212057Abstract: At least one embodiment of the present invention relates to new cycloundecadepsipeptide compounds and to the use of said compounds as a medicament, in particular as antiviral agents, more particularly for preventing or treating Hepatitis C infections or HCV induced disorders.Type: ApplicationFiled: November 6, 2009Publication date: September 1, 2011Applicant: Debio Recherche Pharmaceutique S.A.Inventors: Roland Wenger, Manfred Mutter, Patrick Garrouste, Robert Lysex, Olivier Turpin, Grégoire Vuagniaux, Valérie Nicolas, Laura Novaroli Zanolari, Rafael Crabbé
-
Publication number: 20110212136Abstract: A formulation including injectable biodegradable nanospheres and/or microspheres as a delivery system for chondroitinase ABC (cABC) or a functional derivative of cABC to treat acute and chronic spinal chord injury in a mammal having the same is provided. The biodegradable nanosphere/microsphere formulation releases cABC or a functional derivative of cABC in a time-released manner at the site of the spinal cord injury. cABC infusion can promote axon regrowth and some behavioral recovery. The nanospheres and/or microspheres provided herein include cABC or a functional derivative of cABC loaded within and/or on a biodegradable polymer matrix. In some embodiments of the present invention, the surface of the biodegradable polymer matrix can be modified to target a specific scar site. In addition to providing a nanosphere formulation that include polymeric incorporated cABC, a method of treating a mammal having a spinal cord injury is also provided.Type: ApplicationFiled: September 27, 2010Publication date: September 1, 2011Applicants: The Research Foundation of State University of New York, Syracuse UniversityInventors: Donna J. Osterhout, Julie M. Hasenwinkel, Dennis J. Stelzner
-
Publication number: 20110206638Abstract: The disclosure provides compositions and methods for reducing the mutation rate of a virus, such as an RNA virus or a DNA virus, in a cell infected with the virus by, in one aspect, contacting the cell with an effective amount of an iron chelator or an antioxidant. Also provided are compositions and methods for enhancing the efficacy of an agent or a therapy directed at a virus.Type: ApplicationFiled: January 19, 2011Publication date: August 25, 2011Inventor: Jinah Choi
-
Publication number: 20110208168Abstract: A liquid composition in an osmotic drug delivery system and a dosage form in an osmotic drug delivery system is disclosed comprising an amphiphilic molecule, a non-aqueous liquid solvent, and a pharmaceutically active agent.Type: ApplicationFiled: April 21, 2011Publication date: August 25, 2011Inventors: Rom Ezer Eliaz, Yuanpeng Zhang, Catherine Manya Rohloff, Eric William Weeks, Gunjan Junnarkar
-
Publication number: 20110200556Abstract: Disclosed is a method for preventing the development of head and neck squamous cell carcinoma (HNSCC) in a mammal who is at risk for developing such carcinoma comprising administering an effective amount of a mammalian target of rapamycin (mTOR) inhibitor to the mammal. An example of such inhibitor is rapamycin.Type: ApplicationFiled: August 20, 2009Publication date: August 18, 2011Applicant: THE UNITED STATES OF AMERICA, AS REPRESENTED BY TH E SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIInventors: J. Silvio Gutkind, Panomwat Amornphimoltham, Vyomesh Patel, Alfredo Molinolo, Rakefet Czerninski
-
Publication number: 20110200553Abstract: The present invention provides novel compounds represented by formula I: or pharmaceutically acceptable salts thereof useful for treating flaviviridae viral infection.Type: ApplicationFiled: April 7, 2011Publication date: August 18, 2011Applicant: Vertex Pharmaceuticals IncorporatedInventors: Laval Chan Chun Kong, Jean Bedard, Sanjoy Kumar Das, Nghe Nguyen Ba, Oswy Z. Pereira, Thumkunta Jagadeeswar Reddy, Mohammed Arshad Siddiqui, Wuyi Wang, Constanin G. Yannopoulos
-
Publication number: 20110200558Abstract: A method of treatment for treating or preventing hepatitis C (HepC) in a target subject, including administering to the target subject an effective amount of an immunomodulator compound of Formula A wherein, n is 1 or 2, R is hydrogen, acyl, alkyl or a peptide fragment, and X is an aromatic or heterocyclic amino acid or a derivative thereof, wherein; (i) the immunomodulator compound is administered to the subject at a dosage of greater than 0.Type: ApplicationFiled: August 4, 2009Publication date: August 18, 2011Applicant: SCICLONE PHARMACEUTICALS, INC.Inventors: Israel Rios, Cynthia W. Tuthill
-
Publication number: 20110195110Abstract: Pyrazole urea compounds, pharmaceutical compositions which contain them and methods for treating cancer using them.Type: ApplicationFiled: December 1, 2006Publication date: August 11, 2011Inventors: Roger Smith, Holia N. Hatoum-Mokdad, Louis David Cantin, Donald E. Bierer, Wenlang Fu, Dhanapalan Nagarathnam, Gaetan Ladouceur, Yamin Wang, Herbert Ogutu, Scot Wilhelm, Ian Taylor, Sanjeeva Reddy, Richard Gedrich, Christopher Carter, Aaron Schmitt, Xiaomei Zhang
-
Publication number: 20110195020Abstract: The present invention concerns methods and compositions for making and using bioactive assemblies of defined compositions, which may have multiple functionalities and/or binding specificities. In particular embodiments, the bioactive assembly is formed using dock-and-lock (DNL) methodology, which takes advantage of the specific binding interaction between dimerization and docking domains (DDD) and anchoring domains (AD) to form the assembly. In various embodiments, one or more effectors may be attached to a DDD or AD sequence. Complementary AD or DDD sequences may be attached to an adaptor module that forms the core of the bioactive assembly, allowing formation of the assembly through the specific DDD/AD binding interactions. Such assemblies may be attached to a wide variety of effector moieties for treatment, detection and/or diagnosis of a disease, pathogen infection or other medical or veterinary condition.Type: ApplicationFiled: February 4, 2011Publication date: August 11, 2011Applicant: IBC PHARMACEUTICALS, INC.Inventors: Chien-Hsing Chang, David M. Goldenberg, William J. McBride, Edmund A. Rossi
-
Publication number: 20110195044Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.Type: ApplicationFiled: July 29, 2010Publication date: August 11, 2011Inventor: Jeffrey Lee Romine
-
Patent number: 7993648Abstract: A synergistic adjuvant is provided comprising synergistically effective amounts of at least one type 1 interferon and at least one CD40 agonist, wherein these moieties may be in the same or separate compositions. In addition, fusion proteins and DNA conjugates which contain a type 1 interferon/CD40 agonist/antigen combination are provided. The use of these compositions, protein and DNA conjugates as immune adjuvants for treatment of various chronic diseases such as HIV infection and for enhancing the efficacy of vaccines (prophylactic and therapeutic) is also provided.Type: GrantFiled: May 3, 2007Date of Patent: August 9, 2011Assignee: The Regents of the Universitry of ColoradoInventors: Ross Kedl, Phillip J. Sanchez, Catherine Haluszczak
-
Patent number: 7993639Abstract: In one embodiment, a therapeutic composition containing a pentavalent antimonial is provided. The pentavalent antimonial can be sodium stibogluconate, levamisole, ketoconazole, and pentamidine and biological equivalents of said compounds. Additionally, pentavalent antimonials that can be used in accordance with the present invention may be any such compounds which are anti-leishmaniasis agents. The therapeutic composition of this embodiment contains an effective amount of pentavalent antimonial that can be used in treating infectious diseases. The types of diseases that can be treated with the present invention include, but are not limited to, the following: diseases associated with PTPase activity, immune deficiency, cancer, infections (such as viral infections), hepatitis B, and hepatitis C. The types of cancers that the present embodiment can be used to treat include those such as lymphoma, multiple myeloma, leukemia, melanoma, prostate cancer, breast cancer, renal cancer, bladder cancer.Type: GrantFiled: February 25, 2008Date of Patent: August 9, 2011Assignee: The Cleveland Clinic FoundationInventor: Taolin Yi
-
Patent number: 7993638Abstract: In a cancer treatment combining cell therapy with chemotherapy, autologous CD8+ T cells are obtained from a patient, activated ex vivo by contacting them with xenogenic antigen presenting cells loaded with selected peptide antigen, thereby generating antigen-specific activated cytotoxic T lymphocytes. Such activated CTLs are administered to the patient in conjunction with a lymphodepletion and CTL maintenance regimen comprising a non-myeloblative but lymphdepleting agent, such as cladribine or denileukin diftitox, and interleukin-2 and interferon-?-2b stimulatory cytokines.Type: GrantFiled: February 23, 2007Date of Patent: August 9, 2011Assignee: Janssen Pharmaceutica NVInventors: Zeling Cai, Ann Moriarty, Per A. Peterson, Jon M. Richards
-
Publication number: 20110189129Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: Q-G-A-L-B—W??(I), which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: ApplicationFiled: January 25, 2011Publication date: August 4, 2011Inventors: Yao-Ling Qiu, Ce Wang, Xiaowen Peng, Lu Ying, Hui Cao, Yat Sun Or
-
Publication number: 20110189085Abstract: The present invention provides a composition comprising naked humanized, chimeric, and human anti-CEA antibodies and a therapeutic agent, which is useful for treatment of CEA expressing cancers and other diseases, and methods of use in treatment using this composition.Type: ApplicationFiled: February 18, 2011Publication date: August 4, 2011Applicant: IMMUNOMEDICS, INC.Inventors: David M. Goldenberg, Hans J. Hansen
-
Publication number: 20110189130Abstract: The invention relates to compounds of a general formula (I): wherein Ar1 is an optionally-substituted aryl or heteroaromatic group; R1 is an optionally-substituted lower alkyl, lower alkenyl, lower alkynyl or cyclo-lower alkyl group, or is an aryl, aralkyl or heteroaromatic group optionally having a substituent; R2 is a hydrogen atom, a lower alkyl group, a lower alkenyl group or a lower alkynyl group, or is an aryl, aralkyl or heteroaromatic group optionally having a substituent; R3 is a hydrogen atom or a lower alkyl group; R4 is a hydrogen atom, a halogen atom, a hydroxyl group, a lower alkyl group or a group of —N(R1k)R1m; T and U are a nitrogen atom or a methine group, etc. The compounds of the invention have excellent Weel kinase-inhibitory effect and are therefore useful in the field of medicines, especially treatment of various cancers.Type: ApplicationFiled: March 22, 2011Publication date: August 4, 2011Inventors: Takeshi Sagara, Sachie Otsuki, Satoshi Sunami, Toshihiro Sakamoto, Kenji Niiyama, Fuyuki Yamamoto, Takashi Yoshizumi, Hidetomo Furuyama, Yasuhiro Goto, Makoto Bamba, Keiji Takahashi, Hiroshi Hirai, Toshihide Nishibata
-
Publication number: 20110189083Abstract: The present invention concerns methods and compositions for forming anti-cancer vaccine DNL complexes using dock-and-lock technology. In preferred embodiments, the anti-cancer vaccine DNL complex comprises an antibody moiety that binds to dendritic cells, such as an anti-CD74 antibody or antigen-binding fragment thereof, attached to an AD (anchoring domain) moiety and a xenoantigen, such as CD20, attached to a DDD (dimerization and docking domain) moiety, wherein two copies of the DDD moiety form a dimer that binds to the AD moiety, resulting in the formation of the DNL complex. The anti-cancer vaccine DNL complex is capable of inducing an immune response against xenoantigen expressing cancer cells, such as CD138negCD20+ MM stem cells, and inducing apoptosis of and inhibiting the growth of or eliminating the cancer cells.Type: ApplicationFiled: January 21, 2011Publication date: August 4, 2011Applicant: IBC PHARMACEUTICALS, INC.Inventors: Chien-Hsing Chang, David M. Goldenberg
-
Publication number: 20110182992Abstract: This invention provides novel active agents (e.g. peptides, small organic molecules, amino acid pairs, etc.) peptides that ameliorate one or more symptoms of eye disease and/or other pathologies characterized by an inflammatory response, hi certain embodiment, the peptides resemble a G* amphipathic helix of apolipoprotein J. The agents are highly stable and readily administered via an oral route or via intraocular injection.Type: ApplicationFiled: February 6, 2009Publication date: July 28, 2011Inventors: Gattadahalli M. Anantharamaiah, Martin Rudolf
-
Publication number: 20110182858Abstract: The invention relates to the use of a silibinin component for the production of a medicament that is adapted for parenteral administration for the treatment of viral hepatitis, preferably of hepatitis B or C, in particular for the reduction of the virus load.Type: ApplicationFiled: November 14, 2008Publication date: July 28, 2011Applicant: Madaus GmbHInventors: Lucio Claudio Rovati, Massimo Maria D' Amato, Ulrich Dr. Mengs, Ralf-Torsten Dr. Pohl, Peter, Dr Ferenci
-
Publication number: 20110182850Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.Type: ApplicationFiled: April 7, 2010Publication date: July 28, 2011Inventors: Trixi BRANDL, Prakash Raman, Pascal Rigollier, Mohindra Seepersaud, Oliver Simic
-
Publication number: 20110182982Abstract: One can treat a viral infection such as hepatitis B (HBV), hepatitis C(HCV), and bovine viral diarrhea virus (BVDV) infections via the delivery of pH sensitive liposomes directly into the endoplasmic reticulum (ER) membrane. Two exemplary liposome formulations are DOPE/CHEMS (DC liposomes) and DOPE/CHEMS/PEG-PE (DCPP liposomes). DC and DCPP liposomes can optimize the intracellular delivery of N-butyl deoxynojirimycin (NB-DNJ), and consequently increase the in vivo activity of this iminosugar several orders of magnitude, and could be used in combination with other therapeutic agents such as interferon and/or ribavirin. The optimized release of NB-DNJ directly into the ER can be also applied for the treatment of other viruses, for which NB-DNJ is known to be an effective antiviral, such as human immunodeficiency virus (HIV).Type: ApplicationFiled: March 23, 2011Publication date: July 28, 2011Inventors: Raymond A. Dwek, Norica Nichita-Branza, Stefana Petrescu, Stephanie Pollock, Pauline Rudd, Christopher Scanlan, Nicole Zitzmann
-
Publication number: 20110184379Abstract: Methods for treating Hepatitis infections are provided. In one embodiment, an initial dosage of interferon is administered to a patient, and interferon serum levels and viral load data is collected over time. This data can be used to determine patient-specific pharmacokinetic and pharmacodynamic parameters and then construct patient-specific interferon delivery profiles. Patient-specific delivery profiles can then be used to design patient-specific therapeutic regimens.Type: ApplicationFiled: March 27, 2009Publication date: July 28, 2011Applicant: MEDTRONIC, INC.Inventors: William P. Van Antwerp, Robert C. Hamlen, Eric A. Grovender
-
Publication number: 20110182857Abstract: Liquid pharmaceutical compositions for administration to a mucosal surface, including a therapeutic agent and a pectin with a low degree of esterification are described. Such compositions gel, or can be adapted to gel, at the site of application in the absence of an extraneous source of divalent metal ions.Type: ApplicationFiled: April 1, 2011Publication date: July 28, 2011Applicant: ARCHIMEDES DEVELOPMENT LIMITEDInventors: Peter James WATTS, Lisbeth ILLUM
-
Publication number: 20110182856Abstract: The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt thereof. These compounds inhibit serine protease, particularly the hepatitis C virus NS3-NS4A protease.Type: ApplicationFiled: March 29, 2011Publication date: July 28, 2011Applicant: Vertex Pharmaceuticals IncorporatedInventors: Kevin M. Cottrell, John Maxwell, Qing Tang, Anne-Laure Grillot, Amaud Le Tiran, Emanuele Perola
-
Publication number: 20110177029Abstract: The present invention provides covalent conjugates between a polypeptide and a modifying group, such as a water-soluble polymer (e.g., PEG). The amino acid sequence of the polypeptide includes one or more O-linked glycosylation sequence, each being a substrate for a GIcNAc transferase. The modifying group is covalently linked to the polypeptide via a glycosyl-linking group interposed between and covalently linked to both the polypeptide and the modifying group. In one embodiment, a glucosamine linking group is directly attached to an amino acid residue of the O-linked glycosylation sequence. The invention further provides methods of making polypeptide conjugates. The present invention also provides non-naturally occurring polypeptides that include at least one O-linked linked glycosylation sequence of the invention, wherein each glycosylation sequence is a substrate for a GIcNAc transferase. The invention further provides pharmaceutical compositions that include a polypeptide conjugate of the invention.Type: ApplicationFiled: June 4, 2008Publication date: July 21, 2011Applicant: NOVO NORDISK A/SInventor: Shawn DeFrees
-
Publication number: 20110177030Abstract: Compounds of formula (I): wherein B, X, R3, L0, L1, L2, R2, R1 and RC are defined herein. The compounds are useful as inhibitors of HCV NS3 protease for the treatment of hepatitis C viral infection.Type: ApplicationFiled: April 1, 2011Publication date: July 21, 2011Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Montse LLINAS-BRUNET, Murray BAILEY, Punit BHARDWAJ, Josee BORDELEAU, Pasquale FORGIONE, Elise GHIRO, Vida GORYS, Nathalie GOUDREAU, Sylvie GOULET, Teddy HALMOS, Jean RANCOURT
-
Publication number: 20110177026Abstract: The present invention provides methods for treating a flavivirus infection, including hepatitis C virus (HCV) infection, in an individual suffering from a flavivirus infection. In some embodiments, the methods involve administering to an individual in need thereof an effective amount of an agent that inhibits enzymatic activity of a membrane-bound ?-glucosidase inhibitor. In other embodiments, the methods involve administering to an individual in need thereof effective amounts of an ?-glucosidase inhibitor and at least one additional therapeutic agent.Type: ApplicationFiled: February 10, 2011Publication date: July 21, 2011Applicant: INTERMUNE, INC.Inventors: Lawrence M. Blatt, Hua Tan, Scott D. Seiwert
-
Publication number: 20110171178Abstract: Embodiments relate to proislet peptides, preferably HIP, that exhibit increased stability and efficacy, and methods of using the same to treating a pathology associated with impaired pancreatic function, including type 1 and type 2 diabetes and symptoms thereof.Type: ApplicationFiled: August 29, 2008Publication date: July 14, 2011Applicant: CUREDM GROUP HOLDINGS, LLC.Inventors: Claresa S. Levetan, Victor M. Garsky
-
Publication number: 20110171177Abstract: The present invention embraces Niemann-Pick C1-like 1 protein antagonists and agents that inhibit hepatic virus infection for use in the prevention and treatment of a hepatic virus infection.Type: ApplicationFiled: September 1, 2009Publication date: July 14, 2011Inventors: Susan L. Uprichard, Bruno Sainz
-
Publication number: 20110171175Abstract: This invention relates to compounds of formula I: or a pharmaceutically acceptable salt or mixtures thereof wherein C* represents a diastereomeric carbon comprising a mixture of R and S isomers wherein the R isomer is greater than 50% of the mixture.Type: ApplicationFiled: March 18, 2011Publication date: July 14, 2011Applicant: Vertex Pharmaceuticals IncorporatedInventors: Steven Lyons, Robert B. Perni
-
Patent number: 7976835Abstract: Compositions and methods of preventing or treating a breast cancer are disclosed. The composition and method can utilize an endothelin B agonist and a chemotherapeutic agent as active ingredients to treat a solid tumor in mammals, including humans. Alternatively, the composition and method can utilize an endothelin B antagonist and an optional angiogenesis inhibitor to treat a solid tumor in mammals, including humans.Type: GrantFiled: July 26, 2006Date of Patent: July 12, 2011Assignee: The Board of Trustees of the University of IllinoisInventor: Anil Gulati
-
Publication number: 20110165117Abstract: The PAGE4 gene is expressed in reproductive tissues, and is expressed in reproductive cancers, such as prostate cancer, uterine cancer, and testicular cancer. Immunogenic PAGE4 polypeptides are disclosed herein, as are nucleic acids encoding the immunogenic PAGE4 polypeptides, vectors including these polynucleotides, and host cells transformed with these vectors. These polypeptides, polynucleotides, vectors, and host cells can be used to induce an immune response to PAGE4. Diagnostic methods to detect PAGE4 are also described.Type: ApplicationFiled: February 10, 2011Publication date: July 7, 2011Inventors: Jeffrey Schlom, Kwong-Yok Tsang, Ira H. Pastan
-
Publication number: 20110165122Abstract: Compounds compositions and methods of modulating the immune response are provided. The method uses fusion proteins of a cytokine and an antibody to potentiate the action of the cytokine.Type: ApplicationFiled: November 10, 2010Publication date: July 7, 2011Applicant: The Regents of the University of CaliforniaInventors: Arash Shahangian, Genhong Cheng, Lucy S. Cheng, Kham Moc Trinh, Paul W. Dempsey, Beichu Guo, Sherie L. Morrison
-
Publication number: 20110165073Abstract: B-cell malignancies, such as the B-cell subtype of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, are significant contributors to cancer mortality. The response of B-cell malignancies to various forms of treatment is mixed. Traditional methods of treating B-cell malignancies, including chemotherapy and radiotherapy, have limited utility due to toxic side effects. Immunotherapy with anti-CD20 antibodies have also provided limited success. The use of antibodies that bind with the CD22 or CD19 antigen, however, provides an effective means to treat B-cell malignancies such as indolent and aggressive forms of B-cell lymphomas, and acute and chronic forms of lymphatic leukemias. Moreover, immunotherapy with anti-CD22 and/or anti-CD19 antibodies requires comparatively low doses of antibody protein, and can be used effectively in multimodal therapies.Type: ApplicationFiled: March 15, 2011Publication date: July 7, 2011Applicant: IMMUNOMEDICS, INC.Inventor: David M. Goldenberg
-
Publication number: 20110165121Abstract: Methods for treating human patients infected with the hepatitis C virus using pegylated Type III Interferons (IL-28A, IL-28B and IL-29) alone or in combination with other antiviral agents.Type: ApplicationFiled: June 5, 2009Publication date: July 7, 2011Inventors: Diana F. Hausman, Michael G. Dodds
-
Publication number: 20110165123Abstract: The present invention provides an oligonucleotide which is capable of activating RIG-I and inducing an anti-viral, in particular, an IFN, response in cells expressing RIG-I. The present invention further provides an oligonucleotide which is capable of activating RIG-I and which has target gene-silencing activity. The oligonucleotide of the present invention has a double-stranded section of at least 19, preferably at least 21 bp, at least one 5? triphosphate, and at least one blunt end which bears a 5? triphosphate. The present invention further provides the use said oligonucleotide for inducing an anti-viral, in particular, an IFN, response in vitro and in vivo. The present invention additionally provides the use of said oligonucleotide for preventing and/or treating diseases or conditions such as infections, tumors/cancers, and immune disorders.Type: ApplicationFiled: May 20, 2009Publication date: July 7, 2011Inventors: Gunther Hartmann, Martin Schlee
-
Publication number: 20110165124Abstract: The present invention relates to in vitro methods of determining a susceptibility to non-response to a hepatitis C treatment or a susceptibility to spontaneous hepatitis C clearance in a subject infected with hepatitis C.Type: ApplicationFiled: July 29, 2010Publication date: July 7, 2011Applicants: Centre Hospitalier Universitaire Vaudois, University of BernInventors: Pierre-Yves Bochud, Andri Rauch
-
Publication number: 20110158944Abstract: The present invention provides, inter alia, methods for predicting the sensitivity of a disease, such as cancer, to an ERK1 or ERK2 or MEK inhibitor by detecting the presence of an allele of BRAF in cells mediating the disease. Methods of treatment are also provided.Type: ApplicationFiled: November 26, 2008Publication date: June 30, 2011Inventors: Thomas J. Hosted, Jason S. Simon, Marc M. Delorenzo, Donna Marie Carr, William T. Windsor, Ahmed A. Samatar
-
Publication number: 20110150836Abstract: This application relates to a purine derivative and pharmaceutical compositions which are useful for treating a hepatitis B viral infection or a hepatitis C viral infection.Type: ApplicationFiled: December 16, 2010Publication date: June 23, 2011Applicant: Gilead Sciences, Inc.Inventors: Randall L. HALCOMB, Sundaramoorthi Swaminathan, Daniel B. Tumas
-
Publication number: 20110150835Abstract: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.Type: ApplicationFiled: October 31, 2007Publication date: June 23, 2011Inventors: Srikanth Venkatraman, F. George Njoroge, Wanli Wu, Viyyoor M. Girijavallabhan, Brian A. McKittrick, Jing Su, Francisco Velazquez, Patrick A. Pinto